

Specific Diagnostics Announces that Greg Curhan has joined its Advisory Board

July 2, 2020 - MOUNTAIN VIEW, California

Specific Diagnostics today announces that Greg Curhan has joined its Advisory Board. Mr. Curhan co-founded an investment bank in San Francisco in 2002, Merriman Curhan Ford, after a career in investment banking at some of the leading San Francisco firms that helped finance and advise Silicon Valley startups, building it to a 250-person organization focused on serving fast-growing Information Technology and Life Science companies. He served as the firm's President, and EVP and CFO of its publicly traded parent, MCF Corp. Mr. Curhan is currently a partner at FLG Partners, a leading CFO consulting and board advisory firm in Silicon Valley. He brings both financial and capital markets expertise to Specific as it launches the Reveal rapid susceptibility testing system in Europe in the 2nd half of 2020.

"Greg is joining us at a time when we are scaling up, and his acumen in financial systems as well as the capital markets is a timely addition to the perspective of our lead investor Telegraph Hill Partners," said Dr. Paul A. Rhodes, Specific's founder and CEO. "I look forward to working closely with him to ensure that we build a company that both brings innovative technology to an important medical need while building value for its shareholders."

"I am delighted to have the chance to participate in advising Specific at this exciting stage in its development," said Mr. Curhan. "The company reminds me of some of the most successful that we had the good fortune to finance at our bank: a great technology, with a product relevant to market needs present today, and management and Board focused on execution. I look forward to working with Paul and the Board to help them do what it takes to capitalize on this sort of opportunity. It is clear to me that the global appetite for infectious disease diagnostics is burgeoning, for good reason, and the Company will have a great many choices to navigate. It will be exciting for me to provide them advice from my experience both as an investment banker and CFO of both public and private companies.

Mr. Curhan joined Specific's Advisory Board effective July 1, 2020, with an initial 3-year term.

About Specific

Specific Diagnostics has developed in vitro diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid identification of microorganisms. Its first commercial application applies this fundamental new platform to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as isolate dilutions. Specific is based in Mountain View, CA.

For press inquiries, please contact: press@specificdx.com